The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a not-for-profit organization, dedicated to a close interaction between clinical scientists dealing with bone, joint and muscle disorder, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of Osteoporosis and Osteoarthritis within the comprehensive perspective of health resources utilization.

The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.




Recently published by Springer Healthcare in partnership with the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), the Atlas of Osteoarthritis - Second Edition is now FREE to download for the ESCEO Associate Members.

It includes an updated chapter on the treatment of osteoarthritis and a new chapter on SYSADOAs.

Click here to download the Atlas.



Open Access Symposium

We are also thrilled to announce you that you may discover and follow the UCB Satellite Symposium entitled "Building a stronger future for postmenopausal women with severe osteoporosis" organized during the Virtual WCO-IOF-ESCEO Congress.



Aging clinical and experimental research offers a multidisciplinary forum on the progressing field of gerontology and geriatrics. The areas covered by the journal include: biogerontology, neurosciences, epidemiology, clinical gerontology and geriatric assessment, social, economical and behavioral gerontology. “Aging clinical and experimental research” appears bimonthly and publishes review articles, original papers and case reports.


Discover the official journal of ESCEO on and read the journal contents on
You can get the table of contents of every new issue published in Aging Clinical and Experimental Research. Sign up for the ToC Alert for this journal with your e-mail address. It’s easy and it’s free.


"Why Patented Crystalline Glucosamine Sulfate (pCGS) is different from Other Glucosamines in the Treatment of Osteoarthritis (OA) and Should be Recommended as First Line Therapy"
In December 2015, the paper published by Olivier Bruyère, member of the Scientific Advisory Board of ESCEO, in Seminars in Arthritis and Rheumatism (2014) has benefited from a high visibility in the Asian press: a total of 160 media postings in Thailand, China, Russia and in international outlets with a potential audience of almost 80.000.000 visitors a day.
This is a huge opportunity for ESCEO and for our Osteoarthritis Treatment Algorithm to be seen and read all over the world.

Our 2021 congress in London, United Kingdom